弘信電子(300657.SZ):2021年年報披露日期延至4月29日
格隆匯4月18日丨弘信電子(300657.SZ)公佈,公司因受新冠肺炎疫情影響,公司2021年年度報吿編制相關工作未能按預期完成,經向深圳證券交易所申請,公司2021年年度報吿披露時間由2022年4月2日變更為2022年4月20日。
在此期間,公司及各子公司積極配合協調相關年報編制工作。近期,因新冠肺炎疫情加劇且管控措施升級,對公司年報編制、年度審計及評估機構相關工作造成一定影響,以致無法按照計劃披露年度報吿。為確保2021年年度報吿的質量和信息披露的準確性,經公司申請,公司2021年年度報吿披露時間延期至2022年4月29日(星期五)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.